140 related articles for article (PubMed ID: 34643804)
1. The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study.
Ita MI; Wang JH; Toulouse A; Lim C; Fanning N; O'Sullivan M; Nolan Y; Kaar GF; Redmond HP
Acta Neurochir (Wien); 2022 Mar; 164(3):723-735. PubMed ID: 34643804
[TBL] [Abstract][Full Text] [Related]
2. Plasma circulating cell free messenger RNA as a potential biomarker of melanoma.
Ita MI; Wang JH; Fanning N; Kaar G; Lim C; Redmond HP
Acta Oncol; 2021 Sep; 60(9):1201-1209. PubMed ID: 34086522
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Albrecht LJ; Höwner A; Griewank K; Lueong SS; von Neuhoff N; Horn PA; Sucker A; Paschen A; Livingstone E; Ugurel S; Zimmer L; Horn S; Siveke JT; Schadendorf D; Váraljai R; Roesch A
Clin Transl Med; 2022 Nov; 12(11):e1090. PubMed ID: 36320118
[TBL] [Abstract][Full Text] [Related]
4. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
[TBL] [Abstract][Full Text] [Related]
5. A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas.
Ponnampalam SN; Kamaluddin NR; Zakaria Z; Matheneswaran V; Ganesan D; Haspani MS; Ryten M; Hardy JA
Oncol Rep; 2017 Jan; 37(1):10-22. PubMed ID: 28004117
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Proteomic SWATH-MS Workflow for Profiling Blood Extracellular Vesicles: A New Avenue for Glioma Tumour Surveillance.
Hallal S; Azimi A; Wei H; Ho N; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635403
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the potential of circulating hTERT levels in glioma: can plasma levels serve as an independent prognostic marker?
Gandhi P; Khare R; Garg N
J Neurooncol; 2017 Nov; 135(2):255-261. PubMed ID: 28756592
[TBL] [Abstract][Full Text] [Related]
8. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
9. [Whole-genome messenger RNA profiling reveals genes involved in malignant progression of glioma].
Yang P; Yan W; Zhang W; You G; Bao ZS; Jiang T
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):5-7. PubMed ID: 23578443
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas.
Fan X; Wang Y; Zhang C; Liu X; Qian Z; Jiang T
J Neuroimmunol; 2016 May; 294():27-31. PubMed ID: 27138095
[TBL] [Abstract][Full Text] [Related]
11. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
12. Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.
Jiang S; Eberhart CG; Zhang Y; Heo HY; Wen Z; Blair L; Qin H; Lim M; Quinones-Hinojosa A; Weingart JD; Barker PB; Pomper MG; Laterra J; van Zijl PCM; Blakeley JO; Zhou J
Eur J Cancer; 2017 Sep; 83():9-18. PubMed ID: 28704644
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
14. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
15. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
16. Loss of pigment epithelium derived factor expression in glioma progression.
Guan M; Yam HF; Su B; Chan KP; Pang CP; Liu WW; Zhang WZ; Lu Y
J Clin Pathol; 2003 Apr; 56(4):277-82. PubMed ID: 12663639
[TBL] [Abstract][Full Text] [Related]
17.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
18. HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.
Zhong S; Fan Y; Wu B; Wang Y; Jiang S; Ge J; Hua C; Zhao G; Chen Y; Xu H
World Neurosurg; 2018 Nov; 119():e145-e158. PubMed ID: 30053564
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
Hou C; Ishi Y; Motegi H; Okamoto M; Ou Y; Chen J; Yamaguchi S
J Neurooncol; 2019 Nov; 145(2):201-210. PubMed ID: 31506754
[TBL] [Abstract][Full Text] [Related]
20. TLR2 promotes development and progression of human glioma via enhancing autophagy.
Li C; Ma L; Liu Y; Li Z; Wang Q; Chen Z; Geng X; Han X; Sun J; Li Z
Gene; 2019 Jun; 700():52-59. PubMed ID: 30898699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
